KAMPALA, Uganda — 11 November 2026. The Uganda Cancer Institute is exploring the use of CerviCARE, an artificial-intelligence tool, in a joint cervical-screening project with the Korea Foundation for International Healthcare.
A Daily Monitor report published on 11 November identifies CerviCARE as part of a joint UCI–Korea Foundation for International Healthcare project. Its accompanying image records a dissemination meeting in Kampala on 10 November. The research does not, by itself, establish nationwide access to the device.
CerviCARE is being studied within routine cervical screening in Uganda. The registered protocol compares it with existing visual inspection and examines patient and provider experience. Research approval permits that evaluation; it does not establish nationwide availability, superior clinical outcomes or a replacement for established care.
A comparison inside routine screening services
The Uganda National Council for Science and Technology’s research registry lists Andrew Katumba as the researcher for protocol HS7752ES. The record gives an approval date of 5 June 2026.
The study compares CerviCARE with visual inspection with acetic acid, or VIA, at UCI and an affiliated Mbarara site. Agreement with experienced clinicians and calibration are among its objectives.
This design addresses a practical question: whether an additional assessment can help a screening service work better under the conditions in which Ugandan clinicians and patients actually use it. Agreement between two assessments is one part of that question; it does not alone establish which assessment is correct.
The protocol includes biopsy and laboratory confirmation for a targeted subset of participants with concerning or differing screening findings.
These are planned assessments, not a final tally of cancers diagnosed. A study plan and a results report answer different questions.
HEALTH NEWS
Uganda’s CerviCARE AI Screening Study Explained
Nov 11, 2026
Nov 11, 2026
5 min read
Published
Updated:
KAMPALA, Uganda — 11 November 2026. The Uganda Cancer Institute is exploring the use of CerviCARE, an artificial-intelligence tool, in a joint cervical-screening project with the Korea Foundation for International Healthcare.
A Daily Monitor report published on 11 November identifies CerviCARE as part of a joint UCI–Korea Foundation for International Healthcare project. Its accompanying image records a dissemination meeting in Kampala on 10 November. The research does not, by itself, establish nationwide access to the device.
CerviCARE is being studied within routine cervical screening in Uganda. The registered protocol compares it with existing visual inspection and examines patient and provider experience. Research approval permits that evaluation; it does not establish nationwide availability, superior clinical outcomes or a replacement for established care.
A comparison inside routine screening services
The Uganda National Council for Science and Technology’s research registry lists Andrew Katumba as the researcher for protocol HS7752ES. The record gives an approval date of 5 June 2026.
The study compares CerviCARE with visual inspection with acetic acid, or VIA, at UCI and an affiliated Mbarara site. Agreement with experienced clinicians and calibration are among its objectives.
This design addresses a practical question: whether an additional assessment can help a screening service work better under the conditions in which Ugandan clinicians and patients actually use it. Agreement between two assessments is one part of that question; it does not alone establish which assessment is correct.
ADVERTISEMENT
The protocol includes biopsy and laboratory confirmation for a targeted subset of participants with concerning or differing screening findings.
These are planned assessments, not a final tally of cancers diagnosed. A study plan and a results report answer different questions.
The registry also examines communication, trust, dignity, acceptability and workflow. These are important considerations when adding technology to an examination that can already feel unfamiliar or difficult for patients.
For a service, a useful tool must fit the work of clinicians and support clear explanations. Faster processing or additional images would not, on their own, establish better patient outcomes. Follow-up and access to appropriate care remain part of the pathway.
Research approval is not a national clinical rollout
The registry documents an authorised research activity. It is not an announcement that CerviCARE is available at every district hospital, a price list or a booking service.
ADVERTISEMENT
Nor does the registered comparison establish a national decision to replace VIA or other screening approaches. Claims about diagnostic performance require the study’s results, methods and clinical interpretation, rather than the existence of an AI component.
The World Health Organization’s cervical screening guideline treats screening and treatment as connected parts of prevention. It also distinguishes recommendations for the general population from those for women living with HIV. An equipment announcement should therefore not be read as a new screening schedule for every woman.
People seeking screening should ask their healthcare provider which approved service is appropriate for them and what follow-up is available. Participation in research, routine screening and referral for further assessment are distinct arrangements.
A longer partnership, with delivery questions still to answer
Korean support for Uganda’s cancer services predates this week’s reporting. A KOFIH account published in September 2025 describes cooperation with Korea’s National Cancer Center involving Uganda, including monitoring a cervical-screening pilot and training medical personnel.
That earlier account provides institutional context. It should not be treated as a new November financing agreement or as independent validation of the current study’s results.
ADVERTISEMENT
The public research registration does not set out a complete project budget, device price, patient fee schedule or national expansion timetable. Those details matter for continuity: equipment must sit within a service able to provide trained staff, examinations, further assessment and treatment where required.
WHO’s cervical cancer overview emphasises HPV vaccination, screening and timely treatment. CerviCARE’s potential contribution belongs within that wider prevention and care system. It cannot be assessed simply by counting devices or describing a demonstration as a new service opening.
The next meaningful evidence will be a full account of clinical findings and their limitations, followed by clear decisions about routine use. Patients will also need facility-specific information on availability, charges, eligibility and referral arrangements before the research can be described as an expanded access programme.
Related XTRAfrica coverage examines the separate PRISMA maternal, child and cancer-care programme, Naguru heart-hospital equipment procurement and HIV self-test assembly in Mukono.
ADVERTISEMENT
Related Articles
